Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Jeremy Nichols

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|June 16, 2022
Discovery of 1<i>H-</i>Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase InhibitorsRobert K Leśniak, R Jeremy Nichols, Marcus Schonemann, et al.
European Journal of Medicinal Chemistry|September 1, 2022
Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitorsRobert K Leśniak, R Jeremy Nichols, Marcus Schonemann, et al.
The Biochemical Journal|July 21, 2010
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationR Jeremy Nichols, Nicolas Dzamko, Nicholas A Morrice, et al.
The Biochemical Journal|August 14, 2013
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycleEvy Lobbestael, Jing Zhao, Iakov N Rudenko, et al.
Brain : a Journal of Neurology|December 19, 2017
Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriersYe Zhao, Gayathri Perera, Junko Takahashi-Fujigasaki, et al.
The Journal of Biological Chemistry|February 24, 2019
Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamicsChun-Xiang Wu, Jingling Liao, Yangshin Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2014
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domainJingling Liao, Chun-Xiang Wu, Christopher Burlak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 3, 2016
LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodiesNicolas Dzamko, Amanda M Gysbers, Rina Bandopadhyay, et al.
Frontiers in Molecular Neuroscience|January 3, 2024
PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formationLucia Iannotta, Marco Emanuele, Giulia Favetta, et al.
Cells|March 25, 2022
A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, RespectivelyAntoine Marchand, Alessia Sarchione, Panagiotis S Athanasopoulos, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|June 16, 2022
Discovery of 1<i>H-</i>Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase InhibitorsRobert K Leśniak, R Jeremy Nichols, Marcus Schonemann, et al.
European Journal of Medicinal Chemistry|September 1, 2022
Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitorsRobert K Leśniak, R Jeremy Nichols, Marcus Schonemann, et al.
The Biochemical Journal|July 21, 2010
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationR Jeremy Nichols, Nicolas Dzamko, Nicholas A Morrice, et al.
The Biochemical Journal|August 14, 2013
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycleEvy Lobbestael, Jing Zhao, Iakov N Rudenko, et al.
Brain : a Journal of Neurology|December 19, 2017
Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriersYe Zhao, Gayathri Perera, Junko Takahashi-Fujigasaki, et al.
The Journal of Biological Chemistry|February 24, 2019
Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamicsChun-Xiang Wu, Jingling Liao, Yangshin Park, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2014
Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domainJingling Liao, Chun-Xiang Wu, Christopher Burlak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 3, 2016
LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodiesNicolas Dzamko, Amanda M Gysbers, Rina Bandopadhyay, et al.
Frontiers in Molecular Neuroscience|January 3, 2024
PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formationLucia Iannotta, Marco Emanuele, Giulia Favetta, et al.
Cells|March 25, 2022
A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, RespectivelyAntoine Marchand, Alessia Sarchione, Panagiotis S Athanasopoulos, et al.
Pageof 4